Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Net Income towards Common Stockholders: 2014-2024

Historic Net Income towards Common Stockholders for Rocket Pharmaceuticals (RCKT) over the last 11 years, with Dec 2024 value amounting to -$258.7 million.

  • Rocket Pharmaceuticals' Net Income towards Common Stockholders rose 24.56% to -$50.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$240.9 million, marking a year-over-year increase of 6.65%. This contributed to the annual value of -$258.7 million for FY2024, which is 5.35% down from last year.
  • Rocket Pharmaceuticals' Net Income towards Common Stockholders amounted to -$258.7 million in FY2024, which was down 5.35% from -$245.6 million recorded in FY2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Net Income towards Common Stockholders peaked at -$139.7 million during FY2020, and registered a low of -$258.7 million during FY2024.
  • In the last 3 years, Rocket Pharmaceuticals' Net Income towards Common Stockholders had a median value of -$245.6 million in 2023 and averaged -$242.1 million.
  • Data for Rocket Pharmaceuticals' Net Income towards Common Stockholders shows a maximum YoY slumped of 80.79% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' Net Income towards Common Stockholders stood at -$139.7 million in 2020, then fell by 21.02% to -$169.1 million in 2021, then tumbled by 31.23% to -$221.9 million in 2022, then declined by 10.70% to -$245.6 million in 2023, then dropped by 5.35% to -$258.7 million in 2024.